标题/作者	年份
Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML CD DiNardo, EM Stein, S de Botton, GJ Roboz, JK Altman, AS Mims, ... New England Journal of Medicine 378 (25), 2386-2398	2018
Oxidative stress in cancer JD Hayes, AT Dinkova-Kostova, KD Tew Cancer cell 38 (2), 167-197	2020
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study GK Abou-Alfa, T Macarulla, MM Javle, RK Kelley, SJ Lubner, J Adeva, ... The Lancet Oncology 21 (6), 796-807	2020
Small molecules in targeted cancer therapy: Advances, challenges, and future perspectives L Zhong, Y Li, L Xiong, W Wang, M Wu, T Yuan, W Yang, C Tian, Z Miao, ... Signal transduction and targeted therapy 6 (1), 201	2021
Navigating metabolic pathways to enhance antitumour immunity and immunotherapy X Li, M Wenes, P Romero, SCC Huang, SM Fendt, PC Ho Nature reviews Clinical oncology 16 (7), 425-441	2019
Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies JJ Harding, S Nandakumar, J Armenia, DN Khalil, M Albano, M Ly, J Shia, ... Clinical Cancer Research 25 (7), 2116-2126	2019
Fluorine‐containing drugs approved by the FDA in 2018 H Mei, J Han, S Fustero, M Medio‐Simon, DM Sedgwick, C Santi, ... Chemistry–A European Journal 25 (51), 11797-11819	2019
IDH mutation in glioma: molecular mechanisms and potential therapeutic targets S Han, Y Liu, SJ Cai, M Qian, J Ding, M Larion, MR Gilbert, C Yang British journal of cancer 122 (11), 1580-1589	2020
Mutant isocitrate dehydrogenase inhibitors as targeted cancer therapeutics D Golub, N Iyengar, S Dogra, T Wong, D Bready, K Tang, AS Modrek, ... Frontiers in oncology 9, 417	2019
US FDA approved drugs from 2015–June 2020: a perspective P Bhutani, G Joshi, N Raja, N Bachhav, PK Rajanna, H Bhutani, AT Paul, ... Journal of Medicinal Chemistry 64 (5), 2339-2381	2021
Challenges and opportunities in cancer drug resistance RA Ward, S Fawell, N Floc’h, V Flemington, D McKerrecher, PD Smith Chemical reviews 121 (6), 3297-3351	2020
Current trends in computer aided drug design and a highlight of drugs discovered via computational techniques: A review VT Sabe, T Ntombela, LA Jhamba, GEM Maguire, T Govender, T Naicker, ... European Journal of Medicinal Chemistry 224, 113705	2021
Applications of fluorine-containing amino acids for drug design H Mei, J Han, KD Klika, K Izawa, T Sato, NA Meanwell, VA Soloshonok European journal of medicinal chemistry 186, 111826	2020
Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial AX Zhu, T Macarulla, MM Javle, RK Kelley, SJ Lubner, J Adeva, ... JAMA oncology 7 (11), 1669-1677	2021
Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition JJ Harding, MA Lowery, AH Shih, JM Schvartzman, S Hou, C Famulare, ... Cancer discovery 8 (12), 1540-1547	2018
Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia P Montesinos, C Recher, S Vives, E Zarzycka, J Wang, G Bertani, ... New England Journal of Medicine 386 (16), 1519-1531	2022
Mechanisms of metabolic reprogramming in cancer cells supporting enhanced growth and proliferation C Schiliro, BL Firestein Cells 10 (5), 1056	2021
Ivosidenib: first global approval S Dhillon Drugs 78, 1509-1516	2018
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML S Choe, H Wang, CD DiNardo, EM Stein, S de Botton, GJ Roboz, ... Blood advances 4 (9), 1894-1905	2020
Impact of cross-coupling reactions in drug discovery and development MJ Buskes, MJ Blanco Molecules 25 (15), 3493	2020

1 - 20

计算机程序会自动估算并确定日期和引用次数。